1161 - Gefitinib first line testing for mutations of epidermal growth factor receptor (EGFR) in patients with metastatic non-small cell lung cancer

Page last updated: 13 July 2016

Application Detail

Status

Closed

Description of Medical Service

This application seeks to extend availability of a test already funded on the MBS for use of gefitinib for first-line treatment in patients with locally advanced or metastatic NSCLC.

Description of Medical Condition

There are three histological defined subgroups of NSCLC: (i) adenocarcinoma – often found in an outer area of the lung; (ii) squamous cell carcinoma – usually found in the centre of the lung by an air tube (bronchus); and (iii) large cell carcinoma – may occur in any part of the lung which tends to grow and spread faster than the other two types.

Regardless of the subgroup, NSCLC arises as a consequence of either acquired (somatic) and/or inherited (germ-line) mutations.

Reason for Application

-

Medical Service Type

-

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

14 - 15 September 2011
Consultation Decision Analytic Protocol (PDF 1431 KB)
Consultation Decision Analytic Protocol (Word 704 KB)
Consultation Protocol released for comment 25 July 2011 and closed for comment 18 August 2011

Final Decision Analytic Protocol (DAP) (PDF 394 KB)
Final Decision Analytic Protocol (DAP) (Word 747 KB)

Assessment Report

Public Summary Document - November 2012 (PDF 927 KB)
Public Summary Document - November 2012 (Word 329 KB)

Public Summary Document - August 2013 (PDF 129 KB)
Public Summary Document - August 2013 (Word 99 KB)

Public Summary Document

-

Meetings for this Application

PASC

7 July 2011
14 - 15 September 2011

ESC

11 - 12 October 2012

MSAC

29 - 30 November 2012
1 August 2013